Currently, there are 53.35M common shares owned by the public and among those 50.79M shares have been available to trade.
The company’s stock has a 5-day price change of -53.68% and -52.43% over the past three months. MIST shares are trading -62.71% year to date (YTD), with the 12-month market performance down to -51.38% lower. It has a 12-month low price of $1.12 and touched a high of $2.75 over the same period. MIST has an average intraday trading volume of 1.56 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -54.30%, -55.79%, and -48.13% respectively.
Institutional ownership of Milestone Pharmaceuticals Inc (NASDAQ: MIST) shares accounts for 42.45% of the company’s 53.35M shares outstanding.
It has a market capitalization of $46.95M and a beta (3y monthly) value of 0.97. The earnings-per-share (ttm) stands at -$0.72. Price movements for the stock have been influenced by the stock’s volatility, which stands at 25.86% over the week and 15.12% over the month.
Earnings per share for the fiscal year are expected to decrease by -50.75%, and -30.94% over the next financial year. EPS should shrink at an annualized rate of -7.26% over the next five years, compared to 28.21% over the past 5-year period.
Looking at the support for the MIST, a number of firms have released research notes about the stock. Rodman & Renshaw stated their Buy rating for the stock in a research note on August 22, 2024, with the firm’s price target at $9. Jefferies coverage for the Milestone Pharmaceuticals Inc (MIST) stock in a research note released on June 20, 2023 offered a Hold rating with a price target of $4. Piper Sandler was of a view on April 22, 2022 that the stock is Overweight, while H.C. Wainwright gave the stock Buy rating on March 05, 2021, issuing a price target of $20. Oppenheimer on their part issued Outperform rating on July 29, 2020.
